Parathyroid hormone (PTH) is a potent anabolic agent for the treatment of osteoporosis. However, its mechanism of action in osteoblast and bone is not well understood. In this study, we show that the anabolic actions of PTH in bone are severely impaired in both growing and adult ovariectomized mice lacking bone-related activating transcription factor 4 (ATF4). Our study demonstrates that ATF4 deficiency suppresses PTH-stimulated osteoblast proliferation and survival and abolishes PTH-induced osteoblast differentiation, which, together, compromise the anabolic response. We further demonstrate that the PTH-dependent increase in osteoblast differentiation is correlated with ATF4-dependent up-regulation of Osterix. This regulation involves inte...
Our previous studies showed that fibroblast growth factor 2 (FGF2) intermittent treatment stimulates...
Intermittent parathyroid hormone (PTH) (1-34) is the only anabolic agent currently approved for the ...
The aim of this study was to compare transcriptional regulation in vivo during anabolic bone formati...
Parathyroid hormone (PTH) is a potent anabolic agent for the treatment of osteoporosis. However, its...
Parathyroid hormone (PTH) is a potent anabolic agent for the treatment of osteoporosis. However, its...
Parathyroid hormone (PTH) is a potent anabolic agent for the treatment of osteoporosis. However, its...
Parathyroid hormone (PTH) is currently the only approved anabolic agent for osteoporosis pharmacothe...
Parathyroid hormone (PTH) is currently the only approved anabolic agent for osteoporosis pharmacothe...
Parathyroid hormone (PTH) is currently the only approved anabolic agent for osteoporosis pharmacothe...
Parathyroid hormone (PTH) is currently the only approved anabolic agent for osteoporosis pharmacothe...
Parathyroid hormone (PTH) is currently the only approved anabolic agent for osteoporosis pharmacothe...
[Abstract] Parathyroid hormone (PTH) is a potent bone-forming agent that increases bone mineral dens...
PTH has anabolic and catabolic actions in bone that are not clearly understood. The protooncogene c-...
publisher[Abstract] Parathyroid hormone (PTH) is a potent bone-forming agent that increases bone min...
Our previous studies showed that fibroblast growth factor 2 (FGF2) intermittent treatment stimulates...
Our previous studies showed that fibroblast growth factor 2 (FGF2) intermittent treatment stimulates...
Intermittent parathyroid hormone (PTH) (1-34) is the only anabolic agent currently approved for the ...
The aim of this study was to compare transcriptional regulation in vivo during anabolic bone formati...
Parathyroid hormone (PTH) is a potent anabolic agent for the treatment of osteoporosis. However, its...
Parathyroid hormone (PTH) is a potent anabolic agent for the treatment of osteoporosis. However, its...
Parathyroid hormone (PTH) is a potent anabolic agent for the treatment of osteoporosis. However, its...
Parathyroid hormone (PTH) is currently the only approved anabolic agent for osteoporosis pharmacothe...
Parathyroid hormone (PTH) is currently the only approved anabolic agent for osteoporosis pharmacothe...
Parathyroid hormone (PTH) is currently the only approved anabolic agent for osteoporosis pharmacothe...
Parathyroid hormone (PTH) is currently the only approved anabolic agent for osteoporosis pharmacothe...
Parathyroid hormone (PTH) is currently the only approved anabolic agent for osteoporosis pharmacothe...
[Abstract] Parathyroid hormone (PTH) is a potent bone-forming agent that increases bone mineral dens...
PTH has anabolic and catabolic actions in bone that are not clearly understood. The protooncogene c-...
publisher[Abstract] Parathyroid hormone (PTH) is a potent bone-forming agent that increases bone min...
Our previous studies showed that fibroblast growth factor 2 (FGF2) intermittent treatment stimulates...
Our previous studies showed that fibroblast growth factor 2 (FGF2) intermittent treatment stimulates...
Intermittent parathyroid hormone (PTH) (1-34) is the only anabolic agent currently approved for the ...
The aim of this study was to compare transcriptional regulation in vivo during anabolic bone formati...